TSU-68 (SU6668, Orantinib) (BioDeep_00001884019)

   


代谢物信息卡片


3-(2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl)propionic acid

化学式: C18H18N2O3 (310.1317358)
中文名称: 2,4-二甲基-5-[(1,2-二氢-2-氧代-3H-吲哚-3-基)甲基]-吡咯-3-丙酸, Orantinib
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=C(NC(=C1CCC(=O)O)C)C=C2C3=CC=CC=C3NC2=O
InChI: InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)

描述信息

D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors

同义名列表

3 个代谢物同义名

3-(2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl)propionic acid; 2,4-DIMETHYL-5-[(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)METHYL]-PYRROLE-3-PROPANOIC ACID; TSU-68 (SU6668, Orantinib)



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Changhoon Yoo, Sung-Bae Kim, Jungsil Ro, Seock-Ah Im, Young-Hyuck Im, Jee Hyun Kim, Jin-Hee Ahn, Kyung Hae Jung, Hong Suk Song, Seok Yun Kang, Hee Sook Park, Hyun-Cheol Chung. Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer. Cancer research and treatment. 2016 Apr; 48(2):499-507. doi: 10.4143/crt.2015.089. [PMID: 26194374]
  • Jeeyun Lee, Sang Joon Shin, Ik Joo Chung, Tae Won Kim, Hoo-Geun Chun, Dong Bok Shin, Yeul Hong Kim, Hong Suk Song, Sae-Won Han, Jong Gwang Kim, Sun Young Kim, Young Jin Choi, Hyun Cheol Chung. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Investigational new drugs. 2014 Jun; 32(3):561-8. doi: 10.1007/s10637-014-0075-8. [PMID: 24573743]
  • Agata M Trzcinska-Daneluti, Leo Nguyen, Chong Jiang, Christopher Fladd, David Uehling, Michael Prakesch, Rima Al-awar, Daniela Rotin. Use of kinase inhibitors to correct ΔF508-CFTR function. Molecular & cellular proteomics : MCP. 2012 Sep; 11(9):745-57. doi: 10.1074/mcp.m111.016626. [PMID: 22700489]
  • Kenichiro Enooku, Ryosuke Tateishi, Fumihiko Kanai, Yuji Kondo, Ryota Masuzaki, Tadashi Goto, Shuichiro Shiina, Haruhiko Yoshida, Masao Omata, Kazuhiko Koike. Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times. Journal of gastroenterology. 2012 Jan; 47(1):71-8. doi: 10.1007/s00535-011-0462-2. [PMID: 21935635]
  • Haruyasu Murakami, Yutaka Ueda, Tatsu Shimoyama, Noboru Yamamoto, Yasuhide Yamada, Hitoshi Arioka, Tomohide Tamura. Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors. Cancer chemotherapy and pharmacology. 2011 May; 67(5):1119-28. doi: 10.1007/s00280-010-1405-y. [PMID: 20676674]
  • Yutaka Ueda, Tatsu Shimoyama, Haruyasu Murakami, Noboru Yamamoto, Yasuhide Yamada, Hitoshi Arioka, Tomohide Tamura. Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2011 May; 67(5):1101-9. doi: 10.1007/s00280-010-1404-z. [PMID: 20676675]
  • Fumihiko Kanai, Haruhiko Yoshida, Ryosuke Tateishi, Shinpei Sato, Takao Kawabe, Shuntaro Obi, Yuji Kondo, Makoto Taniguchi, Kazumi Tagawa, Masafumi Ikeda, Chigusa Morizane, Takuji Okusaka, Hitoshi Arioka, Shuichiro Shiina, Masao Omata. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer chemotherapy and pharmacology. 2011 Feb; 67(2):315-24. doi: 10.1007/s00280-010-1320-2. [PMID: 20390419]
  • P Farace, M Galiè, F Merigo, A Daducci, L Calderan, E Nicolato, A Degrassi, E Pesenti, A Sbarbati, P Marzola. Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas. British journal of cancer. 2009 May; 100(10):1575-80. doi: 10.1038/sj.bjc.6605041. [PMID: 19384298]
  • Ryuichi Kitamura, Hisae Asanoma, Sekio Nagayama, Masaki Otagiri. Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68). Drug metabolism and disposition: the biological fate of chemicals. 2008 Jun; 36(6):1003-9. doi: 10.1124/dmd.107.019877. [PMID: 18322074]
  • Ryuichi Kitamura, Yoshio Yamamoto, Sekio Nagayama, Masaki Otagiri. Decrease in plasma concentrations of antiangiogenic agent TSU-68 ((Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid) during oral administration twice a day to rats. Drug metabolism and disposition: the biological fate of chemicals. 2007 Sep; 35(9):1611-6. doi: 10.1124/dmd.106.014068. [PMID: 17567729]
  • Takashi Karashima, Keji Inoue, Satoshi Fukata, Tatsuo Iiyama, Atsushi Kurabayashi, Chiaki Kawada, Taro Shuin. Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice. International journal of oncology. 2007 Apr; 30(4):937-45. doi: . [PMID: 17332933]
  • Bart C Kuenen, Giuseppe Giaccone, Rita Ruijter, Astrid Kok, Casper Schalkwijk, Klaas Hoekman, Herbert M Pinedo. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Sep; 11(17):6240-6. doi: 10.1158/1078-0432.ccr-04-2466. [PMID: 16144927]
  • Pasquina Marzola, Anna Degrassi, Laura Calderan, Paolo Farace, Caterina Crescimanno, Elena Nicolato, Anna Giusti, Enrico Pesenti, Andrea Terron, Andrea Sbarbati, Tinya Abrams, Lesley Murray, Francesco Osculati. In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Jan; 10(2):739-50. doi: 10.1158/1078-0432.ccr-0828-03. [PMID: 14760097]
  • Yasmin Asad, Gillian Cropp, Alison Adams, Anne O'Donnell, Florence Raynaud, Ian Judson, Paul Workman. Validation of liquid chromatography assay for the quantitation of (Z)-3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid (SU006668) in human plasma and its application to a phase I clinical trial. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2003 Feb; 785(1):175-86. doi: 10.1016/s1570-0232(02)00912-1. [PMID: 12535850]
  • G W Krystal, S Honsawek, D Kiewlich, C Liang, S Vasile, L Sun, G McMahon, K E Lipson. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer research. 2001 May; 61(9):3660-8. doi: . [PMID: 11325836]